• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More or Call (407) 374-6986

Wednesday 12/19/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

FDA

  • 2:51 PM

    FDA has confirmed HPPI’s clinical and regulatory pathway for SUBA BCCNS and provided further guidance for anticipated NDA submission PR Newswire TAMPA, Fla., Aug. 6, 2018 TAMPA, Fla., Aug. 6, 2018 /PRNewswire/ — HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced that the U.S. Food and Drug Administration (FDA) has confirmed HPPI’s current clinical and regulatory pathway related to HPPI’s SUBA™-Itraconazole as a treatment for Basal Cell Carcinoma

    Read more
  • 1:28 PM

    Rolling BLA Submission Starting as Early as the End of 2018  – FDA Provides Guidance on Ongoing Requirements VANCOUVER, Washington, June 22, 2018 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company developing new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that it had a productive meeting with the U.S. Food and Drug Administration (FDA) regarding the Company’s planned Biologics License Application (BLA).  Based on FDA feedback, the Company will continue to gather safety and efficacy data

    Read more
  • 12:36 PM

    MINNEAPOLIS, May 31, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that it has launched a new website: www.precisiontherapeutics.com. This new site offers quick and easy access to essential information and features while offering a more comprehensive understanding of the Company’s value proposition and strategic direction in the precision medicine industry. It has a clean uncluttered design, improved functionality and enhanced content that better

    Read more
  • PotNetwork Holding
    8:27 AM

    Reflecting the Company’s Commitment to Excellence in Research, Innovation and Consumer Satisfaction, Exponential Results Continue FT LAUDERDALE, Fla., May 15, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE — PotNetwork Holdings, Inc. (OTC Pink:POTN) is pleased to announce over $2 million in sales revenues recorded for the month of April. Compared with the $1,009,900 the company achieved in April of 2017, April 2018’s revenues represent a 98% year over year increase. PotNetwork Holdings, Inc.’s wholly owned subsidiary Diamond CBD, Inc. recently revealed

    Read more
  • 9:22 AM

    ORLANDO, Fla., March 26, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE– Immune Therapeutics, Inc. (OTCQB:IMUN) (“Immune” “IMUN” or the “Company”), a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies (IRT-103 “Lodonal™” and IRT-101″MENK”) for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDs, today announces that it has received minutes from the Type C meeting held on January 16, 2018, between Immune Therapeutics on behalf of Cytocom, the license holder, and the US Food

    Read more
  • 9:42 AM

    MINNEAPOLIS, March 13, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, announced today that its wholly owned subsidiary, TumorGenesis Inc., has secured a license agreement with SyntArray LLC. This license agreement will advance the Company’s strategic plan to develop the next generation of patient derived (“PDx”) tumor models for precision cancer therapy and drug development by granting it access to SyntArray’s targeted peptide cell capture technology. TumorGenesis is developing a new approach to growing tumor

    Read more
Public Wire Banner